Acumen Pharmaceuticals (ABOS) Q3 2026 earnings summary

Executive summary

• ALTITUDE-AD Phase II top-line results for sabirnetug are expected in November 2026; one confirmatory Phase III may support registration if results are positive.

• Lead EBD candidate IND filing is targeted for mid-2027; ACU301 and ACU401 were nominated in June.

• No product-sale revenue to date; continued operating losses and additional funding needs remain central constraints.

Financial highlights

• Q3 R&D expense was $21.1M vs. $22.0M YoY; lower manufacturing, materials and CRO costs were partly offset by higher EBD work.

• Q3 G&A expense was $4.7M vs. $4.5M YoY; operating loss was $25.8M vs. $26.5M, and net loss was $25.4M vs. $26.5M.

• 9M 2026 R&D expense was $65.4M vs. $84.4M; operating expenses were $79.5M vs. $98.6M, and net loss was $78.8M vs. $96.2M.

• Cash, cash equivalents and marketable securities totaled $78.6M at September 30; operating cash use was $68.9M for 9M 2026 vs. $96.4M YoY.

Outlook and guidance

• ALTITUDE-AD results will include the 18-month iADRS primary endpoint, CDR-SB and other secondary outcomes, safety and ARIA, and fluid and imaging biomarkers.

• Management views 30% iADRS slowing over 18 months as a clear success threshold; low-double-digit total ARIA-E would be supportive safety evidence.

• Current cash and marketable securities are expected to fund activities into early 2027, but not for at least 12 months from financial-statement issuance; substantial doubt about going concern exists.

• EBD IND-enabling work is ongoing; lead-candidate IND filing is targeted for mid-2027.